Home > others & > Lenvatinib Mesylate

Lenvatinib Mesylate

目录号
EY2208
EY2208
EY2208
EY2208

纯度
99.59%
99.59%
99.59%
99.59%

规格
5 mg
10 mg
25 mg
50 mg

原价
220
365
696
989

售价
220
365
696
989

库存
现货
现货
现货
现货

订购
订购
订购
订购
订购
订购

具体折扣请咨询客服

生物活性

Lenvatinib Mesylate 是一种多靶点抑制剂，作用于VEGFR2(KDR)/VEGFR3(Flt-4)最有效，IC50为4 nM/5.2，对VEGFR1/Flt-1作用效果稍弱，作用于VEGFR2/3比作用于FGFR1， PDGFRα/β选择性高10倍左右。
体外研究
体内研究
激酶实验
细胞实验
动物实验
不同实验动物依据体表面积的等效剂量转换表（数据来源于FDA指南）

动物 A (mg/kg) = 动物 B (mg/kg)×动物 B的Km系数/动物 A的Km系数

例如，已知某工具药用于小鼠的剂量为88 mg/kg , 则用于大鼠的剂量换算方法：将88 mg/kg 乘以小鼠的Km系数（3），再除以大鼠的Km系数（6），得到该药物用于大鼠的等效剂量44 mg/kg。

参考文献

[1] Takayuki Nakagawa,et al. Lenvatinib in combination with golvatinib overcomes hepatocyte growth factor pathway-induced resistance to vascular endothelial growth factor receptor inhibitor. Cancer Sci. 2014 Jun; 105(6): 723–730. Published online 2014 Apr 28. doi: 10.1111/cas.12409.
[2] Loredana Lorusso,et al. Lenvatinib and other tyrosine kinase inhibitors for the treatment of radioiodine refractory, advanced, and progressive thyroid cancer. Onco Targets Ther. 2016; 9: 6467–6477. Published online 2016 Oct 20. doi: 10.2147/OTT.S84625.

分子式 C21H19ClN4O4.CH4O3S	分子量 522.97	CAS号 857890-39-2	储存方式 ﹣20 ℃冷藏长期储存。冰袋运输
溶剂（常温）	DMSO	Water <1 mg/mL	Ethanol <1 mg/mL

体内溶解度

Clinical Trial Information ( data from http://clinicaltrials.gov )

NCT Number	Conditions	Interventions	Sponsor/Collaborators	Phases	Start Date	Last Updated
NCT02788708	Fallopian Tube Carcinoma\|Recurrent Ovarian Cancer\|Primary Peritoneal Carcinoma\|Recurrent Endometrial Cancer	Drug: Lenvatinib Mesylate\|Drug: Paclitaxel\|Other: Pharmacological Study	Floor Backes\|Eisai Inc.\|Ohio State University Comprehensive Cancer Center	Phase 1	2016-05-27	2017-02-12
NCT02430714	Thyroid Neoplasms	Drug: Lenvatinib	Eisai Co., Ltd.\|Eisai Inc.		2015-05-20	2017-02-20
NCT02973997	Columnar Cell Variant Thyroid Gland Papillary Carcinoma\|Follicular Variant Thyroid Gland Papillary Carcinoma\|Poorly Differentiated Thyroid Gland Carcinoma\|Recurrent Thyroid Gland Carcinoma\|Stage III Differentiated Thyroid Gland Carcinoma\|Stage III Thyroid Gland Follicular Carcinoma\|Stage III Thyroid Gland Papillary Carcinoma\|Stage IV Thyroid Gland Follicular Carcinoma\|Stage IV Thyroid Gland Papillary Carcinoma\|Stage IVA Differentiated Thyroid Gland Carcinoma\|Stage IVA Thyroid Gland Follicular Carcinoma\|Stage IVA Thyroid Gland Papillary Carcinoma\|Stage IVB Differentiated Thyroid Gland Carcinoma\|Stage IVB Thyroid Gland Follicular Carcinoma\|Stage IVB Thyroid Gland Papillary Carcinoma\|Stage IVC Differentiated Thyroid Gland Carcinoma\|Stage IVC Thyroid Gland Follicular Carcinoma\|Stage IVC Thyroid Gland Papillary Carcinoma\|Tall Cell Variant Thyroid Gland Papillary Carcinoma\|Thyroid Gland Oncocytic Follicular Carcinoma	Other: Laboratory Biomarker Analysis\|Drug: Lenvatinib\|Biological: Pembrolizumab	Academic and Community Cancer Research United\|National Cancer Institute (NCI)	Phase 2	2017-04-01	2017-01-24
NCT03048877	Differentiated Thyroid Cancer	Drug: Apatinib Oral Tablet\|Drug: Placebo Oral Tablet	Peking Union Medical College Hospital	Phase 3	2016-12-01	2017-02-07

注：以上所有数据均来自公开文献，并不保证对所有实验均有效，数据仅供参考。

相关化合物库
使用AMQUAR产品发表文献后请联系我们

AMQUAR产品活动

新闻资讯

Lenvatinib Mesylate

生物活性

体外研究

体内研究

激酶实验

细胞实验

动物实验

不同实验动物依据体表面积的等效剂量转换表（数据来源于FDA指南）

参考文献

Clinical Trial Information ( data from http://clinicaltrials.gov )

相关推荐